Dr. Jack West summarizes the evolving data shaping our understanding of the role of immune checkpoint inhibitors for patients with EGFR- or ALK-positive advanced NSCLC, including more recent data that should change our perspective. (10:25)
Dr. Jack West reviews the preliminary positive result form the IMpower131 trial of chemo +/- atezolizumab immunotherapy and considers what the clinical significance of these findings should be for patients with advanced squamous NSCLC. (9:12)
Dr. Jack West reviews provocative biomarker results on the IMpower150 trial that tested atezolizumab with carboplatin/paclitaxel +/- bevacizumab & revealed strongest benefit of atezo in those with T effector gene signature high expression or high PD-L1. (10:19)
Dr. Jack West reviews the preliminary clinical results on the IMpower150 trial that tested the value of adding the immune checkpoint inhibitor atezolizumab to carbo/paclitaxel/bevacizumab in patients with chemo-naïve advanced non-squamous NSCLC. (11:28)
Dr. Jack West addresses the question of whether the data with various PD-1 and PD-L1 inhibitors in lung cancer management can be viewed as a class effect and whether these immune checkpoint inhibitors should be considered interchangeable. (5:52)